Covalent Peptide Drugs: Making Targeted Binding More Persistent

Reversible drugs bind their targets in a dynamic equilibrium: a drug can bind and dissociate, and target occupancy usually falls as the drug concentration declines. A covalent drug first recognizes its target and then forms a chemical bond at a specific site on the target protein. With an irreversible covalent drug, a bound molecule may continue to act even after free drug has been cleared from the body, until the target protein is renewed or removed. This persistence may extend pharmacological activity, but it also means that the consequences of an incorrect binding event may not quickly subside. Covalent drugs therefore create new design opportunities while demanding more rigorous evaluation of selectivity and safety.

Covalent drugs already have established small-molecule precedents. Some kinase inhibitors suppress cancer-related signaling by forming a covalent bond with a specific amino acid residue on the target protein. Examples include osimertinib, which acts on particular mutant forms of EGFR, and ibrutinib, which acts on BTK. These medicines show that covalent binding is not simply about increasing reactivity. The essential principle is that the drug first recognizes its target and the reaction then occurs at an appropriate site.

This idea has also expanded from small molecules to protein therapeutics. Researchers introduced a covalent-linking design into a HER2-targeting nanobody and used it to deliver radionuclides. In a preclinical mouse study, the covalent nanobody showed more persistent tumor retention. This work remains preclinical, but it suggests an appealing direction: if a targeting molecule can remain in tumor tissue for longer, it may help increase local exposure to a radiopharmaceutical within the tumor.

Peptides are also beginning to enter covalent-drug design. A JACS study incorporated covalent-binding capability into a large-scale macrocyclic peptide screen to identify candidates capable of persistent binding to disease-related targets. In a separate mRNA display study, selected peptides were linked to cytotoxic drugs and showed antitumor activity in cell experiments. These findings demonstrate that covalent peptides can be discovered through screening, but they do not show that such molecules already possess the efficacy, safety, and in-vivo behavior required of a clinical drug.

Covalent peptides merit attention because peptides can recognize relatively large protein surfaces and may bring a reactive group into close proximity to a target. They could serve as tumor-targeting molecules that extend the residence of radionuclides or cytotoxic payloads in tumors, or provide new ways to bind targets that conventional small molecules struggle to reach. Covalent linkage itself, however, does not guarantee that a drug will be more effective. The binding site, the distribution of the target in tumor and normal tissues, and the way the drug is cleared from the body can all influence the final outcome.

The risks therefore cannot be overlooked. If a drug binds a target protein in normal tissue or reacts with an unintended protein, its effects may persist until the relevant protein is renewed. In diseases such as cancer, a higher potential risk can sometimes be weighed against a clear therapeutic benefit. For non-oncology chronic diseases that require years of treatment, the safety threshold should be higher. If a reversible drug can achieve similar efficacy, an irreversible covalent drug generally should not be preferred. This does not mean covalent drugs can never be used long term; it means that, in chronic disease, the additional risk created by persistent binding must be justified.

At present, covalent peptides are better suited to priority exploration in oncology, particularly for targeted radiopharmaceuticals and tumor-targeted drug conjugates. mRNA display offers a new way to discover such molecules, but candidates emerging from screening must still be shown to recognize their targets accurately, form covalent bonds mainly in the intended tissues, and demonstrate acceptable safety in animal studies. Covalent peptides have moved from a design concept toward experimental validation. Whether they can become genuine medicines will depend on converting persistent binding into better therapeutic outcomes while keeping effects on normal tissues within acceptable limits.